Wedbush has increased its 12-month price target for Arvinas Inc. (NASDAQ:ARVN) to $11 from $9, maintaining a Neutral rating on the shares. At the time of Wedbush’s revision, Arvinas shares were quoted at $12.04, which is already higher than the newly stated target and follows a 68% rally over the past six months.
In its note, Wedbush pointed to Arvinas’s fourth-quarter financials and a series of corporate and clinical updates scheduled into 2026 as underpinning factors for the price-target adjustment. Independent analysis via InvestingPro is cited as indicating that the company may still appear undervalued at current market levels, with the platform’s Fair Value output suggesting potential upside. An InvestingPro tip highlighted that Arvinas carries more cash than debt on its balance sheet - a point listed as one of 11 exclusive tips available to subscribers.
The brokerage highlighted multiple near-term clinical program events that it views as material to the company’s outlook. Data for the LRRK2 degrader ARV-102 in patients with Parkinson’s disease remain on schedule and are planned for presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in March 2026. Separately, Arvinas intends to start a Phase 1b trial of ARV-102 in progressive supranuclear palsy in the first half of 2026, and the company is considering potential initiation of a registration study late in 2026.
Wedbush’s note also lays out timing for other pipeline programs. Initial data for the KRAS G12D degrader ARV-806 is now expected in mid-2026, a revision the firm attributed to faster-than-anticipated enrollment in the Phase 1 trial. Updated Phase 1 results for the BCL6 degrader ARV-393 are expected in the second half of 2026. The polyQ-AR program ARV-027 has recently initiated a Phase 1 study, and the HPK1 degrader ARV-6723 is on track to commence a Phase 1 trial in mid-2026.
On the regulatory front, Wedbush noted that the program vepdeg remains open to partnership discussions ahead of its June 5, 2026 PDUFA date.
Those program updates come alongside Arvinas’s reported fourth-quarter 2025 financial results, which fell short of market expectations. The company posted an EPS of -$1.10 for the quarter, missing the consensus forecast of -$0.51 and producing a negative surprise of 115.69%. Revenue for the period totaled $9.5 million, versus the anticipated $36.92 million, a shortfall of 74.27% relative to consensus.
The magnitude of the earnings and revenue misses has prompted investors and analysts to reassess positions and models for Arvinas, and the firm’s results have been noted as a driver for potential adjustments to ratings or forecasts. While Wedbush raised its price target based on the suite of pipeline catalysts and corporate updates, the company’s near-term financial performance and upcoming program readouts are likely to remain focal points for market participants.
Investors are advised to monitor the timing and outcomes of the listed clinical data presentations and the PDUFA decision date, as well as any further corporate disclosures that could affect the company’s cash position or partnership activity.
Summary
Wedbush increased its price target on Arvinas to $11 from $9 while keeping a Neutral rating. The stock trades above that target after a strong six-month rise. The analyst cited fourth-quarter results and a packed 2026 program calendar - including multiple Phase 1 updates, potential registration study starts, and a PDUFA date - as the rationale for the update, even as Arvinas reported significant earnings and revenue shortfalls for Q4 2025.